Prevention of cardiotoxicity among survivors of childhood cancer

Kelley K. Hutchins, Hani Siddeek, Vivian I. Franco, Steven E. Lipshultz

Research output: Contribution to journalReview articlepeer-review

42 Scopus citations


Linked Articles: This article is part of a joint Themed section with the British Journal of Pharmacology on Cardiotoxicity. The rest of the Themed section will appear in a future issue of BJP and will be available at The number of survivors of childhood cancers has increased exponentially over the past few decades. However, these survivors are also at substantially increased long-term risk of morbidity and mortality, especially from treatment-related cardiotoxicity. Preventing these risks is now a priority when treating children and adolescents with cancer. Dexrazoxane reduces the risk of anthracycline-induced cardiotoxicity among adults and children with cancer without reducing its antineoplastic effects or event-free survival. Thus, it should be strongly considered as a part of therapy for children and adolescents treated with anthracyclines.

Original languageEnglish (US)
Pages (from-to)455-465
Number of pages11
JournalBritish Journal of Clinical Pharmacology
Issue number3
StatePublished - 2017
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2016 The British Pharmacological Society


  • cardiotoxicity
  • childhood cancer
  • dexrazoxane
  • survivor


Dive into the research topics of 'Prevention of cardiotoxicity among survivors of childhood cancer'. Together they form a unique fingerprint.

Cite this